Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/12—Ketones
  • A61K31/121—Ketones acyclic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
  • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

• the present invention relates to methods of treating lymphomas with polymeric prodrugs of 7-ethyl-lO-hydroxycamptothecin.
• the invention relates to methods of treating non-Hodglcin's lymphomas with polyethylene glycol conjugates of 7- ethyl- 10-hydroxycaniptothecin.
• Non-Hodgl ⁇ n lymphomas are a group of cancers associated with the immune system such as lymphocytes. NHL may develop in any organs associated with lymphatic system such as spleen, lymph nodes or tonsils. NHL can occur at any age and are often marked by enlarged lymph nodes, fever, and weight loss. NHL is generally grouped into aggressive (fast-growing) and indolent (slow-growing) types. NHL is also classified as either B-cell or T-cell NHL. B-cell NHL includes Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymplioblastic lymphoma, and mantle cell lymphoma.
• T-cell NHL includes mycosis ftmgoides, anaplastic large cell lymphoma, and precursor T-lymphoblastic lymphoma. Lymphomas related to lymphoproliferative disorders following bone marrow or stem cell transplantation are usually B-cell NHL. Prognosis and treatment depend on the stage and type of disease.
• CPT-11 also known as Mnotecan (CPT-11, Camptosar®).
• CPT-11 CPT-11, Camptosar®
• the results associated with these attempts have been thought of as being unsuccessful.
• the present invention provides an alternative for such treatment.
• the treatment includes administering an effective amount of a compound of Formula (I) to a patient in need thereof.
• compounds of Formula (I) used include
• R 1 , R 2 , R 3 and R 4 are independently OH or (L) m -D;
• L is a bifunctional linker
• n is a positive integer; provided that R 1 , R 2 , R3 and R 4 are not ail OH.
• n is from about 28 to about 341, and is preferably about 227.
• the term "residue” shall be understood to mean that portion of a compound, to which it refers, i.e. 7-ethyl-lO-liydroxycamptothecin, amino acid, etc. that remains after it has undergone a substitution reaction with another compound.
• PEG residue shall each be understood to mean that portion of the polymer or PEG which remains after it has undergone a reaction with 7-ethyl-lO-hydroxycamptothecm-containing compounds.
• allcyl shall be understood to include straight, branched, substituted, e.g. halo-, alkoxy-, nitro-, C 1-12 , but preferably C 1-4 alkyls, C 3-8 cycloalkyls or substituted cycloalkyls, etc.
• substituted shall be understood to include adding or replacing one or more atoms contained within a functional group or compound with one or more different atoms.
• substituted alkyls include carboxyalkyls, aminoalkyls, dialkylaminos, hydroxyalkyls and mercaptoalkyls; substituted alkenyls include carboxyalkenyls, aminoalkenyls, dialkenylaminos, hydroxyalke ⁇ yls and mercaptoalkenyls; substituted alkynyls include carboxyalkynyls, aminoalkynyls, dialkynylaminos, hydroxyalkynyls and mercaptoalkynyls; substituted cycloalkyls include moieties such as 4-chlorocyclohexyl; aryls include moieties such as napthyl; substituted aryls include moieties such as 3-bromo phenyl; aralkyls include moieties such as tolyl; heteroalkyls include moieties such as ethylthiophene; substituted alkyls include carboxyal
• Halo shall be understood to include iluoro, chloro, iodo and broino.
• effective amounts and “sufficient amounts” for purposes of the present invention shall mean an amount which achieves a desired effect or therapeutic effect as such effect is understood by those of ordinary skill in the art.
• FIG. 1 schematically illustrates a reaction scheme of preparing four-arm polyethylene glycol acids described in Examples 1-2.
• FTG. 2 schematically illustrates a reaction scheme of preparing 4a ⁇ PEG-Gly-(7-ethyl- 10-hydroxycamptothecin) described in Examples 3-7.
• FIG. 3 shows in vitro metabolism of 4arin-PEG-Gly-(7-ethyl-10-hydroxycamptothecin) as described in Example 10.
• FlG. 4 shows stability of 4arni-PEG-Gly-(7-ethyl-10-hydroxycamptolhecin) as described in Example 12.
• FlG. 5 shows effect of pH on stability of 4arm -PEG-GIy- (7-ethyl- 10- hydroxycamptothecin) as described in Example 12.
• FlG. 6 shows pharmacokinetic profiles of4ami-PEG-Gly-(7-cthyl-10-hydroxy- camptothecin) as described in Example 13,
• the present invention relate to methods of treatment of lymphomas.
• methods of treating patients having non- Hodgkin's lymphomas include administering an effective amount of a compound of Formula (I) to patients in need thereof.
• the compounds of Formula (1) have the structure:
• Ri, R 2 , R 3 and R 4 are independently OH or (L) m -D;
• L is a bifunctional linker
• n is a positive integer, preferably from about 28 to about 341, more preferably from about 114 to about 227, and most preferably about 227; provided that R 1 , R 2 , R 3 and R 4 are not all OH.
• the treatment includes administering a compound having Formula (II)
• the amount administered can range from about 0.3 mg/nT body surface/dose to about 90 mg/m 2 body surface/dose. More preferably, the amount administered ranges from about 0.9 mg/m " to about 30 mg/m 2 .
• the dosage amount shall be understood to mean the amount of 7-ethyl-lO-hydroxyeainptotheci n not the amount of polymeric conjugate administered,
• the present invention includes uses of a compound of Formula
• the polymer portion of the compounds described herein includes multi-arm PEG's.
• the multi-arm PEG's are those described in NOF Corp. Drug Delivery System catalog, Ver. 8, April 2006, the disclosure of which is incorporated herein by reference.
• One particularly preferred multi-arm PEG has the structure:
• n is a positive integer.
• the degree of polymerization for the polymer (n) is from about 28 to about 341 to provide polymers having a total molecular weight of from about 5,000 Da to about 60,000 Da, and preferably from about 114 to about 227 to provide polymers having a total molecular weight of from about 20,000 Da to about 40,000 Da.
• n is about 227,
• blfunctional linkers include an amino acid.
• the amino acid which can be selected from any of the known naturally- occurring L-amino acids is, e.g., alanine, valine, leucine, isoleucine, glycine, serine, threonine, methionine, cysteine, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, lysine, arginine, histidine, proline, and/or a combination thereof, to name but a few.
• L can be a peptide residue.
• the peptide can range in size, for instance, from about 2 to about 10 amino acid residues.
• amino acid analogs and derivates include: 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, beta-aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, piperidinic acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid.
• L groups include glycine, alanine, methionine or sarcosine. More preferably, compounds of the present invention include a glycine as the linker group (L).
• R 21 -R 29 are independently selected from the group consisting of hydrogen, amino, substituted amino, azido, carboxy, cyano, halo, hydroxyl, nitro, silyl ether, sulfonyl, mercapto, C 1-6 alkylmercapto, arylmercapto, substituted arylmercapto, substituted C 1-6 alkylthio, C 1-6 alkyls, C 2-6 alkenyl, C 2-6 alk ynyl, C 3-19 branched alkyl, C 3-8 cycloalkyl, C 1-6 substituted alkyl, C 2-6 substituted alkenyl, C 2-6 substituted alkynyl, C 3-8 substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, C 1-6 heteroalkyl, substituted C 1-6 heteroalkyl, C 1-6 alkoxy, aryloxy, C 1-6 heteroalkoxy, heteroaryloxy, C
• (t), (t ') and (y) are independently selected from zero or a positive integer, preferably from about 1 to about 10; and (v) is 0 or 1.
• L can include:
• (t), (t') and Cy) are independently selected from zero or a positive integer, preferably from about 1 to about 10; and Cv) is 0 or 1.
• the compounds include one up to 10 units of the bifunctional linker. More preferably, one unit of the bifunctional linker is included and thus m is 1. Additional linkers are found in Table 1 of Green wald et al. ⁇ Bioorgaaic & Medicinal Chemistry, 1998, 6:551-562), the contents of which are incorporated by reference herein.
• the prodrugs of the invention employed in treatment are prepared by reacting one or more equivalents of an activated multi-arm polymer with, for example, one or more equivalents per active site of 7-ethyl-IO-hydroxycamptothecin-amino acid conjugate under conditions which are sufficient to effectively cause the amino group to undergo a reaction with the carboxylic acid of the polymer and form a linkage.
• the methods can include;
• Aromatic protecting groups for the 10-hydroxyl group in 7-ethyl-lO-hydroxy- camptothecin are preferred because 7-ethyl-lO-hydroxycamptothecin intermediates thereof have better solubility and can be purified in highly pure form efficiently and effectively.
• silyl-containing protecting groups such as TBDPSCl, TBDMSCl and TMSCl can be used to protect the 10-hydroxyl group in 7-ethyl-lO-hydroxycamptothecin.
• the activated polymer i.e., a polymer containing 1-4 terminal carboxyl acid groups can be prepared, for example, by converting NOF Sunbright-type or other branched polymers having terminal OH groups into the corresponding carboxyl acid derivatives using standard techniques well known to those of ordinary skill. See, for example, Examples 1-2 herein as well as commonly assigned U.S. Patent No. 5,605,976, the contents of which are incorporated herein by reference.
• the first and second coupling agents can be the same or different.
• bifunctional linker groups examples include glycine, alanine, methionine, sarcosine, etc. Alternative syntheses can be used without undue experimentation.
• the compounds administered include:
• One particularly preferred treatment includes administering a compound having the structure
• compositions containing the polymer conjugates of the present invention may be manufactured by processes well known in the art, e.g., using a variety of well-known mixing, dissolving, granulating, levigating, emulsifying, encapsulating, entrapping or lyoph ⁇ izing processes.
• the compositions may be formulated in conjunction with one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Parenteral routes are preferred in many aspects of the invention.
• the compounds of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as physiological saline buffer or polar solvents including, without limitation, a pyrrolidone or dimethylsulfoxide.
• physiologically compatible buffers such as physiological saline buffer or polar solvents including, without limitation, a pyrrolidone or dimethylsulfoxide.
• the compounds described herein may also be formulated for parenteral administration, e.g., by bolus injection or continuous infusion.
• Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers.
• Useful compositions include, without limitation, suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain adjuncts such as suspending, stabilizing and/or dispersing agents.
• compositions for parenteral administration include aqueous solutions of a water soluble form, such as, without limitation, a salt (preferred) of the active compound.
• suspensions of the active compounds may be prepared in a lipophilic vehicle.
• Suitable lipophilic vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate and triglycerides, or materials such as liposomes.
• Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
• the suspension may also contain suitable stabilizers and/or agents that, increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
• the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
• the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers well-known in the art.
• Such earners enable the compounds of the invention to be formulated as tablets, pills, lozenges, dragees, capsules, liquids, gels, syrups, pastes, slurries, solutions, suspensions, concentrated solutions and suspensions for diluting in the drinking water of a patient, premixes for dilution in the feed of a patient, and the like, for oral ingestion by a patient,
• Pharmaceutical preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding other suitable auxiliaries if desired, to obtain tablets or dragee cores.
• Useful excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol, cellulose preparations such as, for example, maize starch, wheat starch, rice starch and potato starch and other materials such as gelatin, gum tragacanth, methyl cellulose, hydr ⁇ xypropyl- methylcellulose, sodium carboxy- methyl cellulose, and/or polyvinylpyrrolidone (PVP).
• disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid. A salt such as sodium alginate may also be used.
• the compounds of the present invention can conveniently be delivered in the form of an aerosol spray using a pressurized pack or a nebulizer and a suitable propellant.
• the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
• the compounds may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
• a compound of this invention may be formulated for this route of administration with suitable polymeric or hydrophobic materials (for instance, in an emulsion with a pharmacologically acceptable oil), with ion exchange resins, or as a sparingly soluble derivative such as, without limitation, a sparingly soluble salt.
• suitable polymeric or hydrophobic materials for instance, in an emulsion with a pharmacologically acceptable oil
• ion exchange resins or as a sparingly soluble derivative such as, without limitation, a sparingly soluble salt.
• Other delivery systems such as liposomes and emulsions can also be used.
• the compounds may be delivered using a sustained-release system, such as semi-permeable matrices of solid hydrophobic polymers containing the therapeutic agent.
• sustained-release materials have been established and are well known by those skilled in the art.
• Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the particular compound, additional stabilization strategies may be employed.
• a therapeutically effective amount refers to an amount of a compound effective to prevent, alleviate or ameliorate 7-ethyl-lO-hydroxycamptothecin-susceptible condition. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the disclosure herein.
• the therapeutically effective amount can be estimated initially from in ritro assays. Then, the dosage can be formulated for use in animal models so as to achieve a circulating concentration range that includes the effective dosage. Such information can then be used to more accurately determine dosages useful in patients. Toxicity and therapeutic efficacy of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals using methods well-known in the art. The dosage, of course, can vary depending upon the dosage form and route of administration. The exact formulation, route of administration and dosage can be selected by the individual physician in view of the patient's condition.
• the presently preferred dosage range for systemic delivery of a compound of this invention will be from about 1 to about 100 mg/kg/week and is preferably from about 2 to about 60 mg/kg/week.
• the treatment of the present invention includes administering the compounds described herein in an amount of from about 0.3 mg/m * body surface/dose to about 90 mg/m" body surface/dose. More preferably, the amounts of the compounds desciibed herein range from about 0.9 mg/m 2 body surface/dose to about 30 mg/m 2 body surface/dose.
• the treatment protocol can be based on a single dose administered once daily or divided into multiple doses which can be given as part of a multi-week treatment protocol. The precise dose will depend on the stage and severity of the condition, the susceptibility of the tumor to the polymer-pro drug composition, and the individual characteristics of the patient being treated, as will be appreciated by one of ordinary skill in the art
• the treatment will be given for one or more days until the desired clinical result is obtained.
• the treatment protocol includes administering the amount ranging from about 1 mg/m" body surface/dose to about 16 mg/irf body surface/dose weekly for three weeks, followed by 1 week without treatment and repeating for about 3 cycles.
• the amount administered per every three weeks can range from about 1.25 mg/m" body surface/dose to about 45 mg/m 2 body surface/dose.
• the compounds administered can be based on body weight.
• the amounts can range from about 0.1 mg/kgbody weight/dose to about 30 mg/kg body weight/dose, preferably, from about 0.3 mg/kg to about 10 mg/kg.
• Specific doses such as 10 mg/kg at q2d x 5 regimen (multiple dose) or 30 mg/kg on a single dose regimen can be administered.
• the dosage amount mentioned is based on the amount of 7-ethyl-lO-hydroxycamptothecin rather than the amount of polymeric conjugate administered.
• the present invention provides methods of treatment of lymphomas.
• the present invention provides methods of treating patients with non- Hodgkin's lymphomas.
• treatment shall be understood to mean inhibition, reduction, amelioration and prevention of tumor growth, tumor burden and metastasis, remission of tumor, or prevention of recurrences of tumor and/or neoplastic growths in patients after completion of treatment.
• the non-Hodgkin's lymphomas being treated can include aggressive (fast- growing) and indolent (slow-growing) types.
• the non-Hodgkin's lymphomas can include B-ccll or T-ceil NHL.
• B-cell NHL includes Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, immimoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, chronic lymphocytic leukima (CLL)/small lymphocytic lymphoma (SLL), extranodal marginal zone B-cell lymphoma-mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-ceil lymphoma, primary mediastinal B-cell lymphoma, lyniphoplasmocytic lymphoma, hairy cell leukimia, and primary central nervous system (CNS) lymphoma.
• CLL chronic lymphocytic leukima
• SLL small lymphocytic lymphoma
• MALT extranodal marginal zone B-cell
• the T-cell NHL includes mycosis fungoides, anaplastic large cell lymphoma, angioimmuiioblastic T-cell lymphoma, extranodal natural killer/T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous panniculitis-Hke T-cell lymphoma, precursor T-lymphoblastic lymphoma. Additional non-Hodgkin's lymphomas are contemplated within the scope of the present invention and apparent to those of ordinary skill in the art.
• the treatment involves lymphomas related to lymphoproliferative disorders following bone marrow or stem cell transplantation such as B-cell NHL.
• 4arm-PEG-OH (12.5 g, 1 eq.) was azeotroped with 220 mL of toluene to remove 35 mL of toluene/water.
• the reaction was kept at 30 0 C for lhour and then was cooled to 25 0 C.
• 40k 4arm-PEG-tBu ester (compound 2, 12 g) was dissolved in 120 mL of DCM and then 60 mL of TFA were added. The mixture was stirred at room temperature for 3 hours and then the solvent was removed under vacuum at 35 0 C. The resulting oil residue was dissolved in 37.5 mL of DCM. The crude product was precipitated with 375 mL of ether. The wet cake was dissolved in 30 mL of 0.5% NaHCO 3 . The product was extracted with DCM twice (2 xl50ml). The combined organic layers were dried over 2.5 g OfMgSO 4 . The solvent was removed under vacuum at room temperature.
• a maximum tolerated dose (MTD) of four-ami PEG conjugated 7-ethyl-IO- hydiOxycamptothecin was studied using nude mice. Mice were monitored for 14 days for mortality and signs of illness and sacrificed when body weight loss was >20% of the pretreatment body weight.
• Table I shows the maximum tolerated dose of compound 9 for bom single dose and multiple dose administration. Each dose for multiple dose administration was given mice every other day for 10 days and the mice were observed for another 4 days, thus for total 14 days. TABLE 1. MTD Data in Nude Mice
• the MTD found for 4a ⁇ ii-PEG-Gly-(7-etliyl-10-hydroxycamptotliecin) (compound 9) was 30 rag/kg when given as single dose, and 10 mg/kg when given as multiple dose (q2d x 5).
• the cytotoxicity provides an indication of the in vitro anti-tumor potency of each compound.
• the in vitro cytotoxicity of PEG-Gly-(7 -ethyl- lO-hydroxycaniptothecin) (compound 9) and CPT-1 1 was determined using a MTS assay. Cells were incubated with drugs for 72 hours at 37 0 C. Following incubation, MTS dye was added and formation of a colored product (fo ⁇ nazan) was measured at 490mn.
• the IC 50 values of compound 9 and CPT-11 indicate that compound 9 has much higher in vitro inhibition in the tested NHL cells than CPT-11.
• the IC 50 of compound 9 ranged between 2 and 20 11M in the Raji and Daudi Burkitt's lymphoma cells and was about 30 to 50 fold more potent than CPT- 1 1.
• EXAMPLE 10 In Vitro Metabolism hi vitro metabolism of PEG-Gly-(7-ethyl-10-hydroxycainptothecin) conjugates (compound 9) was observed in rat hepatocytes. Compound 9 was incubated with rat hepatocytes for 2 hours, pH 7.5, 37 0 C. As shown in Figure 3, 7-ethyl- 10-hydroxy- camptothecin and 7 -ethyl- 10-hydroxycamptotliecin-Gluciiroiiide (7-ethyl- 10-hydroxy- camptothecin-G) were the major metabolites identified, which agrees with known metabolic pathway of 7-ethyl- 10-hydroxycamptothecin in ⁇ ivo. EXAMPLE 11. Properties of PEG Conjugates
• Table 2 shows solubility of PEG-(7-ethyl-10-hydroxycamptothecin) conjugates in aqueous saline solution.
• Compound 9 showed good solubility of up to 4 mg/itiL equivalent of 7-ethyl-lO-hydroxycamptomecin.
• 7-ethyl-10- hydroxycamptothecin was steadily released from the PEG conjugates with a doubling time of 22 to 52 minutes and the release appeared to be pH and concentration dependent as described in the following EXAMPLE 12.
• a 7-ethyl- 10-hydroxycamptothecin is not soluble in saline.
• PEG-Gly-7-ethyl-IO-hydroxycamptothecin conjugates show good stability in saline and other aqueous medium for up to 24 hours at room temperature.
• aqueous stability and hydrolysis properties in rat and human plasma were monitored using UV based HPLC methods.
• 4arm PEG-Gly-(7-ethyl-10- hydroxycamptothecin) conjugates (compound 9) were incubated with each sample for 5 minutes at room temperature.
• mice Tumor free Balb/C mice were injected with a single injection of 20 mg/kg 4arm PEG-Gly-(7-ethyl-10-hydroxyca ⁇ nptotliecin) conjugates. At various time points mice were sacrificed and plasma was analyzed for intact conjugates and released 7-ethyl- 10- hydroxy-camptothecin by HPLC. Pharmacokinetic analysis was done using non- compartmental analysis (WinNonlin). Details are set forth in Table 3. Table 3. Pharmacokinetic Data
• pegylation of 7-ethyl-lO-hydroxycamptothecm allows long circulation half life and high exposure to native drug 7-ethyl-l 0-hydroxycamptothecin.
• Enterohepatic circulation of 4arm P£G-Gly-(7-emyl-l O-hydroxycamptothecin) conjugates was observed.
• the pharmacokinetic profile of PEG-Gly-(7-cthyI-10- hydroxycamptothecin) in mice was biphasic showing a rapid plasma distribution phase during the initial 2 hours followed by a 18-22 hours terminal elimination half-life for the conjugate and a concomitant 18-26 hours terminal elimination half-life for 7-ethyl-lO- hydroxycamptothecin.
• pharmacokinetic profiles of 4arm PEG-Gly-(7 -ethyl- 10-hydroxy- camptothecin) were investigated in rats.
• does levels of 3, 10 and 30 mg/kg (7- ethyl-10-liydroxycamptothecin equivalent) were used.
• the pharmacokinetic profiles in rats were consistent with those of mice.
• the apparent half life of released 7-ethyl-l 0-hydroxycamptothecin from 4arm PEG-GIy conjugates in mice or rats is significantly longer than the reported apparent half life of released 7-etliyl-lO-hydroxycamptothecin from CPT-11 and the exposure of released 7-ethyl-l O-hydroxycamptothecin from 4 arm PEG-GIy-(7-elhyl-10- hydroxy c am ptotliecin) is significantly higher than the reported exposure of released 7- ethyl-10-liydroxycamptotheciii from CPT-11.
• the clearance of the parent compound was OJ 5 niL/hr/kg in rats.
• the estimated volume of distribution at steady state (Vss) of the parent compound was 5.49 mL/kg.
• the clearance of the released 7-ethyl-10- hydroxycamptothecin was 131 mL/hr/kg in rats.
• the estimated Vss of released 7-ethyl- 10-hydroxycamptothecin was 2384 niL/kg In rats. Enterohepatic circulation of released 7- ethyl- 10-hydroxycamptothecin was observed both in mice and rats.
• the antitumor efficacy of compound 9 of Example 7 was measured in Raji Burkitt's lymphoma xenografted mice.
• Disseminated xenograft tumors were established in SCID CBI 7 mice by injecting 2.5 x 10 6 human Burkitt's lymphoma cells (Raji) intravenously. The mice were then randomly assigned to each test group (10 mice per group). 30 mg/kg body weight of compound 9 was injected intravenously as a single dose at day 1 in the group treated with compound 9. In the mice treated with CPT-11, 60 mg/kg body weight of CPT-1 1 was injected. Therapy was initiated 1 day post injection of cells.
• the amount of compound 9 administered is based on the amount of 7-ethyl- 10-hydroxycamptothecin, not the amount of polymeric conjugate administered.
• mice were monitored daily for any signs of illness, general behavioral changes and survival. Body weight was also monitored. Mice bearing tumors that showed open necrotic lesions were sacrificed. Mice losing more than 20% of body weight were also humanely sacrificed. For all the treatment groups, mice were monitored for tumor growth and survival. All mice were euthanized by CCH inhalation at the termination of study. The results of cure rate and increased life span (ILS) are set forth in Table 4.
• mice treated with compound 9 had 50% cure rate in the single dose treatment.
• the mice treated with compound 9 showed 90% in the multiple dose treatment. None of the mice treated with CPT- 1 1 were cured in either single dose or multiple dose treatment.
• cure is understood to mean there are no signs of tumor by gross observation 100 days after completion of treatment.
• results indicate that compounds described herein have utility in treating patients with non-Hodgldn's lymphomas such as Burkitt's lymphoma.
• the results also indicate that the compounds described in can be an alternative to therapy based on CPT-1 1.
• EXAMPLE 15 In Vivo DATA- Efficacies In Daudi Human Burkitt's Lymphoma Xenografted Mice Model
• the antitumor efficacy of compound 9 was also measured in Daudi Burkilt's lymphoma xenografted mice.
• Disseminated xenograft tumors were established in SCID CB 17 mice by injecting 2.5 x 10 6 human Burkitt's lymphoma cells (Daudi) intravenously. The mice were then randomly assigned to each test group (10 mice per group). Early treatment therapy was initiated 1 day post injection of tumor cells. Delayed treatment was initiated 7 days after injection of tumor cells.
• mice treated with CPT-I 60 mg/kg body weight of CPT-11 was injected.
• the control group of mice received saline.
• mice were monitored daily for any signs of illness, general behavioral changes and survival. Body weight was also monitored. Mice bearing tumors that showed open necrotic lesions were sacrificed. Mice losing more than 20% of body weight were also humanely sacrificed. For all the treatment groups, mice were monitored for tumor growth and survival. All mice were euthanized by CCh inhalation at the termination of study. The results of cure rate and increase life span (ILS) are set forth in Table 5.
• mice treated with compound 9 had
• mice treated with compound 9 also showed 90% cure rate in the delayed treatment single dose treatment. None of the mice treated with CPT-11 were cured.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicinal Preparation (AREA)

Priority Applications (9)

Applications Claiming Priority (6)

Publications (2)

Family

ID=39184444

Family Applications (1)

Country Status (11)

Families Citing this family (21)

Family Cites Families (61)

• 2007
  • 2007-02-09 US US11/704,607 patent/US7462627B2/en not_active Expired - Fee Related
  • 2007-08-17 CN CN2007800343014A patent/CN101707888B/zh not_active Expired - Fee Related
  • 2007-08-17 AU AU2007297042A patent/AU2007297042B2/en not_active Ceased
  • 2007-08-17 EP EP07814225A patent/EP2073809A4/en not_active Withdrawn
  • 2007-08-17 BR BRPI0716807-1A patent/BRPI0716807A2/pt not_active IP Right Cessation
  • 2007-08-17 CA CA002662920A patent/CA2662920A1/en not_active Abandoned
  • 2007-08-17 KR KR1020147035602A patent/KR20150005721A/ko not_active Application Discontinuation
  • 2007-08-17 JP JP2009528374A patent/JP2010503691A/ja active Pending
  • 2007-08-17 MX MX2009002853A patent/MX2009002853A/es not_active Application Discontinuation
  • 2007-08-17 WO PCT/US2007/076241 patent/WO2008033643A2/en active Application Filing
  • 2007-08-17 KR KR1020097005140A patent/KR20090059117A/ko not_active Application Discontinuation
• 2008
  • 2008-11-20 US US12/274,474 patent/US7723351B2/en not_active Expired - Fee Related
• 2009
  • 2009-02-19 IL IL197122A patent/IL197122A0/en unknown
• 2010
  • 2010-04-19 US US12/762,434 patent/US8299089B2/en not_active Expired - Fee Related

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events